- Home
- PBYI vs IPHA Comparison
PBYI vs IPHA Comparison
Compare PBYI & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBYI
- IPHA
- Stock Information
- Founded
- PBYI 2010
- IPHA 1999
- Country
- PBYI United States
- IPHA France
- Employees
- PBYI N/A
- IPHA N/A
- Industry
- PBYI Biotechnology: Pharmaceutical Preparations
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- PBYI Health Care
- IPHA Health Care
- Exchange
- PBYI Nasdaq
- IPHA Nasdaq
- Market Cap
- PBYI 138.4M
- IPHA 160.1M
- IPO Year
- PBYI N/A
- IPHA 2019
- Fundamental
- Price
- PBYI $3.07
- IPHA $2.38
- Analyst Decision
- PBYI Strong Buy
- IPHA Strong Buy
- Analyst Count
- PBYI 1
- IPHA 1
- Target Price
- PBYI $7.00
- IPHA $11.00
- AVG Volume (30 Days)
- PBYI 275.3K
- IPHA 31.8K
- Earning Date
- PBYI 05-08-2025
- IPHA 03-27-2025
- Dividend Yield
- PBYI N/A
- IPHA N/A
- EPS Growth
- PBYI 37.78
- IPHA N/A
- EPS
- PBYI 0.62
- IPHA N/A
- Revenue
- PBYI $230,468,000.00
- IPHA $20,831,349.00
- Revenue This Year
- PBYI N/A
- IPHA $209.83
- Revenue Next Year
- PBYI N/A
- IPHA $83.96
- P/E Ratio
- PBYI $4.92
- IPHA N/A
- Revenue Growth
- PBYI N/A
- IPHA N/A
- 52 Week Low
- PBYI $2.23
- IPHA $1.29
- 52 Week High
- PBYI $5.20
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- PBYI 51.76
- IPHA 71.42
- Support Level
- PBYI $2.88
- IPHA $2.13
- Resistance Level
- PBYI $3.14
- IPHA $2.34
- Average True Range (ATR)
- PBYI 0.14
- IPHA 0.14
- MACD
- PBYI 0.01
- IPHA 0.04
- Stochastic Oscillator
- PBYI 64.00
- IPHA 90.07
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.